All Posts, News

ConcertAI’s TeraRecon and Bot Image, Inc. Partnership 

 TeraRecon, on March 18, 2023

CAMBRIDGE, Mass., Mar. 18,2023  /PRNewswire/ — The Eureka Clinical AI platform, from ConcertAI’s TeraRecon, now provides clinicians with the state-of-the-art artificial intelligence and deep learning technology necessary to bring Fast, effective, accurate Prostate Cancer Screening and Detection/Diagnosis using bpMRI and AI to the masses through solutions from Bot Image, Inc.

Bot Image, Inc. with operations and headquarters in NE and Maine, had received FDA clearance for prostate cancer (PCa) screening and detection/diagnosis in July 2022. Bot Image’s prostate AI software, ProstatIDTM, is poised to address the increasing demand for increased accuracy in PCa detection and diagnosis which has been shown to significantly increase cancer detection while decreasing false positives that lead to expensive and unwarranted biopsies. Additionally, with its unique FDA clearance for Screening using low cost bi-parametric MRI, ProstatID can be used similarly as Mammograms are used for Breast cancer screening. The important distinction here from the trademarked Manogram® is that the later uses expensive and time-consuming contrast agents in conjunction with the MRI which precludes it from being an effective screening tool. Not so with ProstatID which substitutes artificial intelligence for contrast agents in detecting the cancer**. This makes ProstatID an ideal tool for active surveillance to monitor progression of the disease which according to recent findings reported in the NEJM1 where it was reported that waiting and watching; ie, surveillance of the cancer, can be more appropriate than intervention; thus saving healthcare dollars and undesirable side effects of treatments.

“With a global installed base of ~1,900 health sites, TeraRecon represents a significant and immediate distribution opportunity for the unique analysis capabilities of Bot Image, Inc.’s prostate cancer solutions. We are thrilled to be a part of the TeraRecon AI partner ecosystem and to offer our solutions on the Eureka Clinical AI Platform and to all healthcare providers needing these services in a streamlined and best-in-breed ecosystem that TeraRecon offers,” said Dr. Randall W. Jones Bot Image, Inc. CEO Eureka Clinical AI by TeraRecon is a robust platform powering 1st party, 2nd party, and 3rd party algorithms on one consolidated platform that integrates seamlessly into the PACS and provides a console to see all results and conversations across the patient’s health care teams, and allows clinicians to directly interact with the AI to ensure accurate and holistic algorithm training.

Learn more about the Eureka Clinical AI platform capabilities and algorithms that span across neurology, radiology, cardiology, oncology, and more: 

About ConcertAI: ConcertAI is the leader in Real-World Evidence (RWE) and AI technology solutions for life sciences and health care. Our mission is to accelerate insights and outcomes for patients through leading real-world data, AI technologies, and scientific expertise in partnership with the leading biomedical innovators, health care providers, and medical societies. For more information, visit us at

About TeraRecon: Serving ~1,900 clinical sites globally, TeraRecon, a ConcertAI company, is a Best in KLAS solution provider for AI-empowered radiology, oncology, cardiology, neurology, and vascular surgery. Awarded the KLAS Category Leader for Advanced Visualization, TeraRecon solutions are independent of any one manufacturer’s imaging equipment or PACS system, allowing a single, unified, and simplified clinical workflow that can improve efficiencies and deliver actionable physician-guided insights. For more information, visit us at

About Bot Image: Bot Image, Inc.’s mission is to blend artificial intelligence (AI) with other diagnostic mediums and bring about substantial improvements in clinical outcomes where it matters most: Improved cancer screening, detection, classification, and grading using non-invasive imaging technologies such as MRI and CT. The Omaha-based medical imaging software company’s first product, ProstatID, blends AI with MRI to detect potentially cancerous lesions, assigning a cancer probability score to each, and aid physician’s in the patient diagnosis.

Manogram® is a registered trademark of AdMeTech of Boston, MA.

** Note, we are not suggesting that the patient not receive an mpMRI as this is up to the physician but ProstatID can assist in interpretation of mpMRI as well.

  1. Hamdy, Donovan, Lane, Metcalfe, et. al., Fifteen-year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer, NEJM, March 11, 2023. DOI: 10.1056/NEJMoa2214122